Mark Alan Goldberg
Insider Reports History
- Location
- Lexington, MA
- Signature
- /s/ Melissa Masse, Attorney-in-Fact
- All insider transactions
- Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date
Holdings reported by Mark Alan Goldberg:
| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| GLYCOMIMETICS INC | Director | Common Stock | 24,828 | $74,484 | $3.00 | 29 Mar 2024 | Direct |
| GLYCOMIMETICS INC | Director | Common Stock | 11,497 | $34,491 | $3.00 | 29 Mar 2024 | By family trusts |
| Blueprint Medicines Corp | Director | Common Stock | 0 | $0 | $128.18 | 17 Jul 2025 | Direct |
| ImmunoGen, Inc. | Director | Common Stock | 0 | $0 | $29.30 | 12 Feb 2024 | Direct |
| ImmunoGen, Inc. | Director | Deferred Share Unit | 0 | $0 | $29.30 | 12 Feb 2024 | Direct |
| ImmunoGen, Inc. | Director | Restricted Stock Unit | 0 | $0 | $29.30 | 12 Feb 2024 | Direct |
| GLYCOMIMETICS INC | Director | Stock Option (right to buy) | 40,000 | 01 May 2024 | Direct | ||
| IDERA PHARMACEUTICALS, INC. | Director | Stock Option (Right to Buy) | 26,000 | 23 Jun 2022 | Direct | ||
| Blueprint Medicines Corp | Director | Stock Option (Right to Buy) | 0 | 17 Jul 2025 | Direct | ||
| ImmunoGen, Inc. | Director | Stock Option (Right to Buy) | 0 | $4.56 | 12 Feb 2024 | Direct |